Anzeige
Mehr »
Samstag, 07.06.2025 - Börsentäglich über 12.000 News
Starke Zahlen: EBITDA bei 9 Mio.?€ - Startet jetzt die Neubewertung?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PWDV | ISIN: KYG0330A1013 | Ticker-Symbol: 3NK
Tradegate
06.06.25 | 07:52
0,870 Euro
-2,79 % -0,025
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
ALPHAMAB ONCOLOGY Chart 1 Jahr
5-Tage-Chart
ALPHAMAB ONCOLOGY 5-Tage-Chart
RealtimeGeldBriefZeit
0,8650,91506.06.
0,8750,91006.06.

Aktuelle News zur ALPHAMAB ONCOLOGY Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrALPHAMAB-B (09966): INSIDE INFORMATION ANNOUNCEMENT - COMPLETION OF PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER1
DiALPHAMAB-B (09966): VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES OF JSKN003 FOR PRESENTATION AT 2025 ASCO ANNUAL MEETING1
DiALPHAMAB-B (09966): INSIDE INFORMATION ANNOUNCEMENT - PLACING OF EXISTING SHARES BY CONTROLLING SHAREHOLDER1
29.05.ALPHAMAB-B (09966): GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD SCHEME2
26.05.ALPHAMAB-B (09966): NEXT DAY DISCLOSURE RETURN1
20.05.ALPHAMAB-B (09966): FORM OF PROXY FOR USE AT THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, JUNE 12, 20251
20.05.ALPHAMAB-B (09966): NOTICE OF ANNUAL GENERAL MEETING-
20.05.ALPHAMAB-B (09966): (1) PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE NEW SHARES (INCLUDING RESELL OR TRANSFER TREASURY SHARES); ...1
ALPHAMAB ONCOLOGY Aktie jetzt für 0€ handeln
30.04.ALPHAMAB-B (09966): VOLUNTARY ANNOUNCEMENT - THE INTERIM ANALYSIS OF A PIVOTAL PHASE II/III CLINICAL TRIAL OF KN026 HAS MET THE PRIMARY ENDPOINT OF PFS-
30.04.ALPHAMAB-B (09966): VOLUNTARY ANNOUNCEMENT - RESEARCH UPDATES OF JSKN021 AND JSKN022 FOR PRESENTATION AT 2025 AACR ANNUAL MEETING1
28.04.ALPHAMAB-B (09966): 2024 ENVIRONMENTAL, SOCIAL AND GOVERNANCE REPORT-
28.04.ALPHAMAB-B (09966): 2024 ANNUAL REPORT-
23.04.ALPHAMAB-B (09966): (1) GRANT OF SHARE OPTIONS UNDER THE POST-IPO SHARE OPTION SCHEME; AND (2) GRANT OF AWARD SHARES UNDER THE RESTRICTED SHARE AWARD ...4
25.03.ALPHAMAB-B (09966): ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 20241
18.03.ALPHAMAB-B (09966): VOLUNTARY ANNOUNCEMENT - JSKN003 WAS GRANTED BREAKTHROUGH THERAPY DESIGNATION BY THE NMPA3
06.03.ALPHAMAB-B (09966): DATE OF BOARD MEETING2
04.03.ALPHAMAB-B (09966): POSITIVE PROFIT ALERT-
27.12.24ALPHAMAB-B (09966): VOLUNTARY ANNOUNCEMENT - APPROVAL FROM CDE FOR JSKN003 TO INITIATE A PHASE III CLINICAL STUDY FOR TREATMENT OF OC1
24.12.24ALPHAMAB-B (09966): VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CDE FOR A PHASE I/II CLINICAL TRIAL OF JSKN0332
19 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1